Researchers working with ultrasound contrast developer Sonus Pharmaceuticalspresented data about a new contrast agent, QW7437, at last week'sAmerican Heart Association meeting in New Orleans. The Bothell,WA, company said QW7437 is a third-generation
Researchers working with ultrasound contrast developer Sonus Pharmaceuticalspresented data about a new contrast agent, QW7437, at last week'sAmerican Heart Association meeting in New Orleans. The Bothell,WA, company said QW7437 is a third-generation agent that studiesindicate may be capable of producing myocardial perfusion at lowdoses with no hemodynamic effects.
Researchers from the University of California at San Diegoworking with the new agent presented data from animal studiesfor the first time at a major medical conference. QW7437 is aphase-shift emulsion that is stabilized with a negative-chargedsurfactant.
Investigators at the AHA meeting also presented data on thecompany's lead EchoGen agent, including an animal study by DukeUniversity researchers in which EchoGen was used to make 3-D measurementsof the left ventricle muscle mass in a single cardiac cycle.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.